Press release
Dr. Jeff Geschwind to Present at the Prestigious Veith Symposium 2025 in New York City
For more than four decades, the Veith Symposium has provided leading physicians, surgeons, and researchers from around the world a forum to exchange knowledge, discuss emerging technologies, and debate pressing clinical challenges in vascular medicine. This year's event will be held from November 18-22, 2025, at the New York Hilton Midtown, and is expected to feature over 1,300 fast-paced presentations covering cutting-edge topics in vascular, endovascular, and oncologic care.
Dr. Geschwind's participation highlights his continued dedication to advancing interventional oncology-a field he helped pioneer and shape into one of the most dynamic areas in modern medicine. His presentations will emphasize the need for multidisciplinary collaboration that bridges imaging, research, and clinical data to improve patient outcomes. "The Veith Symposium has long been considered the meeting of reference for vascular medicine," said Jeff Geschwind, MD. "I am especially happy that the AIM symposium was given a dedicated day this year during the Veith Symposium to present the latest data to interventional radiologists and other specialties. It is therefore an honor to share the stage with global experts and contribute to the continued growth of interventional oncology".
About the Veith Symposium
The Veith Symposium addresses a critical need in global healthcare: bridging the gap between medical practice and the latest advances in vascular and endovascular treatment. The conference provides an accredited platform for physicians to earn CME credits while engaging in discussions on new techniques, technologies, and therapeutic strategies. Topics range from pharmacologic and surgical innovations to imaging breakthroughs, ensuring that participants receive the most current, unbiased, and evidence-based education available.
Jointly accredited by the Cleveland Clinic Center for Continuing Education, the symposium awards up to 45.75 AMA PRA Category 1 Credits Trademark , affirming its importance as one of the most credible continuing education opportunities for vascular and interventional specialists. Each year, the Veith Symposiumt fosters dialogue between experts, challenges established conventions, and promotes clinical excellence through over a thousand presentations, panel discussions, and video case studies.
About Dr. Jeff Geschwind
Dr. Jeff Geschwind currently serves as the Medical Director for Oncology, Image-Guided Therapy, and Imaging Core Lab at NAMSA, one of the largest clinical research organizations in the United States. He is also a Medical Advisor to HistoSonics, a company developing non-invasive image-guided therapy for cancer, and a consultant for Cage Pharma-a firm he founded in 2009 that develops cancer drugs targeting tumor metabolism. Additionally, Dr. Geschwind acts as a scientific consultant for Philips Healthcare, advising on oncology and image-guided technologies.
Dr. Geschwind's distinguished academic background began at the University of Pennsylvania and Boston University School of Medicine, followed by residency training at the University of California, San Francisco as an NIH Resident-Scholar.
He later completed his fellowship training in Vascular and Interventional Radiology at Johns Hopkins University School of Medicine, and remained on faculty after completing his training, eventually becoming Professor of Radiology, Surgery, and Oncology and Director of the Division of Vascular and Interventional Radiology.
Over his career, Dr. Geschwind has published nearly 300 peer-reviewed scientific manuscripts, authored the first textbook on Interventional Oncology, and co-edited Abram's Angiography, a leading reference in interventional radiology. His research in tumor metabolism and targeted liver cancer therapies has earned multiple NIH grants, philanthropic funding, and industry recognition. Notably, his Google Scholar H-index of 86 places him among the most cited radiologists in the world-reflecting the lasting impact of his scientific work.
After nearly two decades at Johns Hopkins, Dr. Geschwind was recruited to Yale School of Medicine as Chairman of Radiology and Biomedical Imaging and Radiologist-in-Chief at Yale-New Haven Hospital. There, he established a new laboratory dedicated to liver cancer and interventional oncology, supported by major NIH funding. His leadership has helped advance minimally invasive cancer treatment, inspiring a new generation of physicians and researchers committed to medical innovation.
Advancing the Future of Image-Guided Oncology
Dr. Geschwind's session at the AIM at Veith program will underscore the importance of integrating cancer biology, imaging science, and clinical outcomes into a unified framework for patient-centered care. His contributions not only redefine how patients with liver cancer are treated but also reinforce the vital role of interventional radiology in the broader medical landscape.
The Veith Symposium 2025 promises to be a milestone event for the medical community, offering new insights, interactive learning opportunities, and international collaboration.
For more information on the event, visit www.veithsymposium.org [http://www.veithsymposium.org/].
To learn more about Dr. Jeff Geschwind's research, publications, and professional achievements, visit https://jeffgeschwind.com [https://jeffgeschwind.com/].
Media Contact:
Press Office - Dr. Jeff Geschwind
Website: https://jeffgeschwind.com [https://jeffgeschwind.com/]
Media Contact
Company Name: Veith Symposium
Contact Person: Jeff Geschwind
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dr-jeff-geschwind-to-present-at-the-prestigious-veith-symposium-2025-in-new-york-city]
Country: United States
Website: https://jeffgeschwind.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dr. Jeff Geschwind to Present at the Prestigious Veith Symposium 2025 in New York City here
News-ID: 4262629 • Views: …
More Releases from ABNewswire
Multimodal Transport Market worth $159.30 billion in 2032
Multimodal Transport Market By Configuration (Two Mode, Three Mode, Hybrid/ Others), End-use Industry (Retail, Food & Beverages, Pharmaceuticals & Healthcare, Chemicals & Materials, Manufacturing), Region - Global Forecast to 2032
The multimodal transport market [https://www.marketsandmarkets.com/Market-Reports/multimodal-transport-market-145586443.html] is projected to grow from USD 98.61 billion in 2025 to USD 159.30 billion in 2032 at a CAGR of 7.1%.
The multimodal transport market is experiencing strong momentum as supply chains shift from single-mode freight movement…
Connected Car Security Market worth $6.99 billion in 2032
Connected Car Security Market by Type (Endpoint, Application, Network, Security), Solution (Software & Hardware), Application (TCU, Infotainment, ADAS, Communication Modules), Form (In-vehicle, External Cloud), EV Type & Region- Global Forecast to 2032
The connected car security market [https://www.marketsandmarkets.com/Market-Reports/connected-car-security-market-109563614.html] is projected to grow from USD 3.37 billion in 2025 to USD 6.99 billion by 2032, at a CAGR of 11.0%.
The rapid rise in vehicle connectivity and V2X communication technologies is driving strong…
MicroCaps in the News: BMXI, RNWF, TGGCF, SIGL - Gold, Fusion Energy, and Quantu …
As investors search for high-impact microcap stocks, several OTC and TSX-listed companies are releasing news tied to hard assets, clean energy innovation, and next-generation cybersecurity. Recent updates from Brookmount Gold, Renewal Fuels, Toogood Gold, and Signal Advance introduce identifiable near- and mid-term catalysts that are drawing increased attention from small-cap and speculative growth investors heading into 2026.
Brookmount Gold (OTC: BMXI) reported continued progress on its North American asset spinoff, completing…
FOCUSfactor Registered Beverage Emerges as a Growth Catalyst for Synergy CHC Cor …
Synergy CHC Corp. (NASDAQ: SNYR) is gaining renewed investor attention as its FOCUSfactor Registered functional beverage platform scales rapidly through the Company's already-established retail ecosystem-built on the strength of its 25-year FOCUSfactor Registered brain health supplement legacy. By leveraging long-standing national distribution relationships, Synergy is accelerating beverage adoption without the execution risk typically associated with launching a new consumer brand.This beverage expansion underpins Roth Capital Partners' Buy rating and 12-month…
More Releases for Geschwind
The Right Equipment for Supreme Security
Leading online retailer of video and home security systems announces license plate cameras for perfect readability.
Melville, NY, February 22, 2011 -- SpyTown, a premier online retailer for all security needs and loss prevention provide high quality video security systems and cameras to ensure supreme safety in any home or business. When in need to catch license plate information, SpyTown carries specially designed cameras to allow readability of the numbers and…
